Financial Plan Inc’s Ensysce Biosciences ENSC Stock Holding History

Financial Plan Inc’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,000	Closed	-$22.1K	–	97
2025 Q4	$22.1K	Buy	+24,000	New	+$44.5K	﹤0.01%	91

Other funds holding ENSC

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TIAM2

Tru Independence Asset Management 2 Portland, Oregon $163M AUM 18.06% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Financial Plan Inc's ENSC Position: Q1 2026 in Review

Financial Plan Inc sold out of Ensysce Biosciences (ENSC) in Q1 2026, closing a stake of 24,000 shares — an estimated $22.1K sold.

Financial Plan Inc first reported a position in ENSC in Q4 2025 and held it in 1 quarter. The position peaked at $22.1K in Q4 2025. 15 funds tracked by Wall St. Rank hold ENSC as of Q1 2026.

Financial Plan Inc reported no remaining Ensysce Biosciences position as of Q1 2026 after selling out during the quarter.
Financial Plan Inc sold 24,000 Ensysce Biosciences shares in Q1 2026, an estimated $22.1K.
Financial Plan Inc first reported a position in Ensysce Biosciences in Q4 2025 and held it in 1 quarter.
Financial Plan Inc's Ensysce Biosciences position peaked at $22.1K in Q4 2025.
15 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q1 2026.

Based on Financial Plan Inc's 13F filing for Q1 2026, filed 27 Apr 2026.